Ibrutinib (Ibruvica ™)
Ibrutinib is an immunotherapy medicine used in treatment of CLL, SLL and Mantle Cell Lymphoma with a promising outlook in treatment of other subtypes of lymphoma.
Ibrutinib works by blocking activity of a specific protein called Bruton’s tyrosine kinase (BTK). By blocking this protein BTK ibrutinib may help move abnormal cells out of their nourishing environments in the lymph nodes, bone marrow and other organs where is gets excreted. BTK is also found in normal healthy B cells so this action of blocking may cause side effects.
Ibrutinib is an oral tablet that you take every day.
Ibrutinib may have the following side effects:
• Irregular heart beat (Atrial fibrillation)
• Lowered blood counts
• Muscle and bone pain
Some patients may be able to enrol in a clinical trial testing ibrutinib. Ask your doctor if there are any clinical trials suitable for you.
IMBRUVICA (Ibrutinib) is now indicated for the treatment of:
• Adult patients with CLL/SLL who have received at least one prior therapy, or adult patients with previously untreated CLL/SLL
• Patients with CLL/SLL with deletion 17p
• Patients with MCL who have received at least one
•Adult patients with Waldenstrom's macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for combination chemo-immunotherapy
"At 72 years of age I can still ride over 300kms in Parliament2Opera
and take 2 Ibrutinib tablets each day", Michael